<DOC>
	<DOCNO>NCT03003364</DOCNO>
	<brief_summary>This phase I/IIa , randomize , double-blind , single-dose , placebo control , two-way crossover clinical trial 10 patient 18 65 year age affect chronic traumatic spinal cord enter study objective ass safety obtain efficacy data intrathecal administration expand Wharton 's jelly mesenchymal stem cell .</brief_summary>
	<brief_title>Intrathecal Administration Expanded Wharton 's Jelly Mesenchymal Stem Cells Chronic Traumatic Spinal Cord Injury</brief_title>
	<detailed_description>This phase I/IIa , randomize , double-blind , single-dose , placebo control , two-way crossover clinical trial 10 patient 18 65 year age affect chronic traumatic spinal cord enter study objective ass safety obtain efficacy data intrathecal administration ( L3 level ) expand Wharton 's jelly mesenchymal stem cell . Following administration patient remain 24 h hospital thereafter discharge . For first period , follow-up plan day 7 1 , 3 6 month . At month 6 , patient treat crossover way ( second period ) follow schedule follow-up . Results initially assess 12 month follow-up thereafter 24 36 month part long-term follow-up .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>1 . Single spinal cord injury lesion cause trauma 2 . Affected cord segment T2 T11 , confirm magnetic resonance 3 . Complete paraplegia ( ASIA A ) 4 . Chronic disease state ( 12 month 5 year injury ) 5 . Patients 18 65 year age , sex 6 . Life expectancy &gt; 2 year 7 . Confidence patient attend followup visit . 8 . Given informed consent write 9 . Patient able understand study procedures 1 . Mechanic ventilation 2 . Lesion affect multiple level 3 . Lesion length superior 3 spinal cord segment , assess magnetic resonance 4 . Penetrating trauma affect spinal cord 5 . Positive serology HIV , HBV , HCV syphilis 6 . Pregnant woman without proper anticonceptive measure accord investigator , breath feed 7 . Use metal implant complicate MRI interpretation 8 . Planned spinal surgery within subsequent 24 month enter trial 9 . Intrathecal medication immunosuppressive drug previous 60 day . 10 . Neurodegenerative disease 11 . Significant abnormal laboratory test contraindicate patient 's participation study . 12 . Neoplasia within previous 5 year , without complete remission 13 . Patient difficulty communicate 14 . Participation another clinical trial treat investigational medicinal product previous 60 day 15 . Contraindication lumbar punction 16 . Other pathologic condition circumstance could complicate participation patient study accord medical criterion 17 . The patient accept followedup period could exceed clinical trial length</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>